Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containing the Inducible Caspase 9 Safety Switch in Subjects With Triple Negative Breast Cancer

Next Previous
Trial Profile

Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containing the Inducible Caspase 9 Safety Switch in Subjects With Triple Negative Breast Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; IC9 CAR T Cell Therapy (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Adverse reactions

Most Recent Events

  • 25 Jun 2026 Planned End Date changed from 1 May 2028 to 1 May 2030.
  • 25 Jun 2026 Planned primary completion date changed from 1 May 2026 to 22 May 2028.
  • 13 Dec 2024 Trial design presented at the 47th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top